CYP2C19*17 — increased clopidogrel metabolism
One copy of the CYP2C19*17 increased-function variant detected.
You have one copy of a more-active version of the CYP2C19 gene.
Rapid metabolizer phenotype. Tends toward stronger clopidogrel response (more active drug formed) and faster clearance of some PPIs and antidepressants.
Your body activates clopidogrel a bit more efficiently than average, and clears some heartburn medicines (PPIs) and antidepressants faster too.
What this means
*17 is an *increased-function* CYP2C19 allele — the mirror image of the reduced-function *2. Carriers process clopidogrel into its active form more efficiently. For most drugs the practical effect is small, but for acid-suppression therapy and a few antidepressants, ultra-rapid metabolizers may need dose adjustments to achieve therapeutic effect.
CYP2C19 is an enzyme in your liver that processes a number of common medicines. The *17 version of this gene produces an enzyme that works faster than average — the opposite of the slow *2 version. If you take the blood-thinner clopidogrel, you'll actually activate it slightly better than most people. For most drugs the practical effect is small, but for stomach-acid medicines like omeprazole and a few antidepressants, the drug may pass through your system too quickly at standard doses, so your doctor might adjust the dose upward.
Caveats
- The clinical effect is meaningful but usually small.
- Some studies suggest a slightly increased bleeding risk from clopidogrel in *17 carriers.
- This is informational unless you are prescribed a relevant drug.